A detailed history of Cx Institutional transactions in Abb Vie Inc. stock. As of the latest transaction made, Cx Institutional holds 70,374 shares of ABBV stock, worth $12.7 Million. This represents 0.62% of its overall portfolio holdings.

Number of Shares
70,374
Previous 59,147 18.98%
Holding current value
$12.7 Million
Previous $10.1 Million 37.0%
% of portfolio
0.62%
Previous 0.48%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$163.84 - $199.33 $1.84 Million - $2.24 Million
11,227 Added 18.98%
70,374 $13.9 Million
Q2 2024

Jul 11, 2024

BUY
$154.79 - $180.76 $75,382 - $88,030
487 Added 0.83%
59,147 $10.1 Million
Q1 2024

Apr 15, 2024

BUY
$159.82 - $182.1 $819,077 - $933,262
5,125 Added 9.57%
58,660 $10.7 Million
Q4 2023

Jan 12, 2024

BUY
$137.6 - $154.97 $1,376 - $1,549
10 Added 0.02%
53,535 $8.3 Million
Q3 2023

Oct 17, 2023

BUY
$133.59 - $154.65 $1.61 Million - $1.86 Million
12,052 Added 29.06%
53,525 $7.98 Million
Q2 2023

Jul 26, 2023

SELL
$132.51 - $164.9 $338,298 - $420,989
-2,553 Reduced 5.8%
41,473 $5.59 Million
Q1 2023

May 04, 2023

BUY
$144.61 - $166.54 $719,434 - $828,536
4,975 Added 12.74%
44,026 $7.02 Million
Q4 2022

Feb 03, 2023

SELL
$138.31 - $165.87 $2.88 Million - $3.45 Million
-20,814 Reduced 34.77%
39,051 $6.31 Million
Q3 2022

Nov 04, 2022

BUY
$134.21 - $153.93 $6.37 Million - $7.31 Million
47,481 Added 383.41%
59,865 $8.04 Million
Q2 2022

Aug 02, 2022

BUY
$137.62 - $174.96 $10,321 - $13,122
75 Added 0.61%
12,384 $1.9 Million
Q1 2022

May 09, 2022

SELL
$131.98 - $163.75 $149,269 - $185,201
-1,131 Reduced 8.42%
12,309 $2 Million
Q4 2021

Jan 18, 2022

BUY
$107.43 - $135.93 $45,335 - $57,362
422 Added 3.24%
13,440 $1.82 Million
Q3 2021

Nov 10, 2021

SELL
$106.4 - $120.78 $24,365 - $27,658
-229 Reduced 1.73%
13,018 $1.4 Million
Q2 2021

Aug 04, 2021

BUY
$105.21 - $117.21 $50,395 - $56,143
479 Added 3.75%
13,247 $1.49 Million
Q1 2021

Apr 15, 2021

BUY
$102.3 - $112.62 $10,946 - $12,050
107 Added 0.85%
12,768 $1.38 Million
Q4 2020

Jan 12, 2021

BUY
$80.49 - $108.67 $63,265 - $85,414
786 Added 6.62%
12,661 $1.36 Million
Q3 2020

Oct 13, 2020

BUY
$85.91 - $100.83 $19,587 - $22,989
228 Added 1.96%
11,875 $1.04 Million
Q2 2020

Aug 06, 2020

BUY
$73.37 - $98.18 $204,262 - $273,333
2,784 Added 31.41%
11,647 $1.14 Million
Q1 2020

Apr 29, 2020

SELL
$64.5 - $97.79 $5,998 - $9,094
-93 Reduced 1.04%
8,863 $675,000
Q4 2019

Jan 21, 2020

SELL
$72.13 - $90.25 $29,212 - $36,551
-405 Reduced 4.33%
8,956 $793,000
Q3 2019

Oct 10, 2019

SELL
$62.98 - $75.72 $112,167 - $134,857
-1,781 Reduced 15.98%
9,361 $709,000
Q2 2019

Jul 17, 2019

BUY
$65.7 - $83.98 $118,325 - $151,247
1,801 Added 19.28%
11,142 $810,000
Q1 2019

Apr 03, 2019

SELL
$77.14 - $90.79 $553,942 - $651,962
-7,181 Reduced 43.46%
9,341 $753,000
Q4 2018

Jan 14, 2019

SELL
$77.85 - $96.01 $1.02 Million - $1.26 Million
-13,080 Reduced 44.19%
16,522 $1.52 Million
Q3 2018

Oct 09, 2018

BUY
$88.91 - $98.84 $177,553 - $197,383
1,997 Added 7.23%
29,602 $2.8 Million
Q2 2018

Jul 12, 2018

BUY
$89.78 - $106.23 $1.3 Million - $1.53 Million
14,434 Added 109.59%
27,605 $2.56 Million
Q2 2018

Jul 12, 2018

BUY
$89.78 - $106.23 $1.18 Million - $1.4 Million
13,171 New
13,171 $1.25 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Cx Institutional Portfolio

Follow Cx Institutional and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cx Institutional, based on Form 13F filings with the SEC.

News

Stay updated on Cx Institutional with notifications on news.